Navigation Links
Diffusion Pharmaceuticals Announces Results of Phase I Human Trial of Lead Drug Candidate, Trans Sodium Crocetinate (TSC) and Completion of a $4.5 Million Private Placement
Date:9/28/2007

CHARLOTTESVILLE, Va., Sept. 28 /PRNewswire/ -- Diffusion Pharmaceuticals LLC, a clinical-stage drug development company commercializing first-in-class drugs utilizing a novel mechanism of action that enhances oxygen diffusion, today announced the results of a Phase I safety trial of its lead drug candidate, trans sodium crocetinate (TSC). In addition, the company announced the completion of a $4.5 million private placement, the proceeds of which will support the company's overall growth and advance TSC into Phase II clinical trials in early 2008.

Diffusion Pharmaceuticals' initial safety study was a double-blind, placebo-controlled, dose-escalation study designed to evaluate the tolerability and pharmacokinetics of a single intravenous bolus injection of TSC in healthy human subjects. The study demonstrated that TSC is very well-tolerated, raising no significant clinical issues in humans at doses significantly higher than the doses to be used in upcoming clinical trials in patients.

"Successful completion of this study is a key milestone in the clinical development of TSC and significantly advances our lead product candidate toward commercialization," said David G. Kalergis, Chief Executive Officer of Diffusion Pharmaceuticals. "The results of our Phase I trial and recent preclinical studies, coupled with completion of the private placement, will enable us to move quickly into Phase II proof-of-concept studies with TSC in two diverse patient populations -- peripheral vascular disease and cancerous brain tumors -- both of which exhibit oxygen deprivation at the cellular level," said Kalergis.

The company's next clinical study will examine the safety and effects of TSC on oxygenation levels of cancerous tumor tissue in primary brain tumor patients who have glioblastoma multiforme (GBM) and will be undergoing a surgical procedure for tumor biopsy and/or tumor resection. Further trials in GBM patients will examine the safety and effects of TSC,
'/>"/>

SOURCE Diffusion Pharmaceuticals LLC
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Supply of Radiopharmaceuticals Hampered by Attacks
2. FDA approves Watson Pharmaceuticals Oxytrol patch
3. Ranbaxy Pharmaceuticals Inc awarded the prestigious outstanding supplier award received from Wal-Mart
4. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
5. United Kingdom Is Lagging In Novelty In The Field Of Pharmaceuticals
6. Top Pharmaceuticals Influence Doctors Prescriptions
7. More Study On Side Effects of ADHD Drug Needed: Shire Pharmaceuticals
8. Personalized Medicine and Innovative Pharmaceuticals
9. New lease of life for asthmatics by Accentia Biopharmaceuticals
10. Pravastatin Launched by Watson Pharmaceuticals
11. Tata Industries picks up stake in Indigene Pharmaceuticals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... 10, 2014 CBPartners, a global leader ... launched a new website. The redesigned site boasts ... access to the firm’s thought pieces, blog posts, and ... platform to showcase our insights, capabilities, and to provide ... Chief Executive Officer, Cyrus Chowdhury. “An enhanced online ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Parker ... protecting the rights of victims injured by defective ... a lawsuit over allegations that the woman’s hidden, ... a power morcellator used during a routine laparoscopic ... against Richard Wolf Medical Instruments Corporation over its ...
(Date:7/10/2014)... 10, 2014 (HealthDay News) -- Nature, not nurture, may ... individual chimpanzees, a new study finds. "As is ... to cognitive [thinking] abilities in chimpanzees," William Hopkins of ... in a news release from the journal Current ... into the evolution of intelligence in humans, Hopkins, team ...
(Date:7/10/2014)... Kristen Fischer HealthDay Reporter ... help ease the hot flashes that often accompany menopause, new ... than 50 percent of menopausal women, said Dr. Taraneh Shirazian, ... at the Icahn School of Medicine at Mount Sinai Hospital ... more than 10 hot flashes a day, and she added ...
(Date:7/10/2014)... announcement that the "Mississippi Baby," believed to have been ... have detectable levels of the virus, the Elizabeth Glaser ... but remains hopeful that the scientific breakthrough that allowed ... than two years will continue to help researchers understand ... , "Although we had high hopes that the ...
Breaking Medicine News(10 mins):Health News:CBPartners Announces New Website 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 2Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 3Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 4Health News:Couple Sues Over Alleged Cancer Risk Associated with use of a Power Morcellator During the Woman's Laparoscopic Fibroid Removal Procedure, Parker Waichman Comments 5Health News:Like Humans, Chimps' Smarts May Rely on Genes 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 2Health News:Losing Weight May Ease Hot Flashes, Study Finds 3Health News:Despite setback, 'Mississippi Baby' represents significant breakthrough in effort to end AIDS 2
... cord by a couple of minutes can have a beneficial effect ... developed countries the tendency of doctors is to cut the umbilical ... problems and allow the mother to hold her baby without delay. ... time ensues before the umbilical cord is severed. ,The ...
... Public Health has been established at Kattankulathur, off Chennai, capital ... will be functioning as part of the SRM Medical College ... SRM University, said the School of Public Health had been ... from the US and the other from the UK. ...
... is a mother’s prayers answered. Five years back Timothy Bingham ... named// it after him- the Bingham syndrome. ,The boy ... like attacks, which rendered him totally paralyzed. It left him in ... of his eyes. ,Yet light has finally broken through ...
... ‘mild, mellow and giggling’ and ‘loved-up with a trippy edge’. ... regular party clubber// in UK’s hot nightspots. , ... by vets. Yet these are now increasingly offered ... , The rocketing use of these drugs have forced UK’s ...
... smoking is well known. But there is one more effect ... you look old, when you are actually// not. It has ... ,Dermatology researchers in the U.S. investigated the effects ... to sunlight. The study observed 82 people who smoked and ...
... paucity of anesthesiologists in the province of Ontario, evident in ... tide over such a situation, Ontario has created two additional ... times for patients. This strategy has proved its weight in ... time tested measure to improve patient care. ...
Cached Medicine News:Health News:New School of Public Health in Chennai 2
(Date:7/10/2014)... 11, 2014  Major advances in radiation therapy ... being highlighted in a three-day Oncology Summit taking ... July, 2014.  Renowned national and international cancer experts from ... and exchange knowledge on modern technologies making treatment ... The Summit will address a ...
(Date:7/10/2014)... 11. Juli 2014  Dilon Technologies, ... die molekulare Bildgebung, einschließlich molekularer Bildgebung ... CE-Zulassung für sein Navigator ® -Gamma-Sondensystem ... das Produkt jetzt europaweit vertreiben. Dilon ... der europäischen Länder ausgedehnt und bereits ...
(Date:7/10/2014)...  The U.S. Department of Health and Human Services ... (UH) Case Medical Center Seidman Cancer Center totaling $4.7 ... improving care for patients with complex cancer. ... a unique model developed at UH to enhance care ... or demonstrated need for high health care utilization.  ...
Breaking Medicine Technology:Improving quality and access to advanced cancer care in India and South Asia 2Improving quality and access to advanced cancer care in India and South Asia 3Improving quality and access to advanced cancer care in India and South Asia 4Improving quality and access to advanced cancer care in India and South Asia 5Dilon erhält CE-Zulassung für sein Navigator-Gamma-Sondensystem 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 2University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 3University Hospitals Case Medical Center Awarded $4.7 Million Grant from U.S. Department of Health and Human Services 4
... New to Antiretroviral Therapy Respond ... Similarly to Men and ... once-daily or twice-daily dosing of Abbott,s (NYSE:,ABT) protease inhibitor Kaletra(R) ... amount of HIV-1),and improving the immune system (increasing CD4 cells) ...
... a,biopharmaceutical company engaged in the discovery and development ... announced today,that Genentech, a collaborator, has moved a ... into a phase 1 clinical trial,that has begun ... and tolerability of both single and multiple doses ...
Cached Medicine Technology:Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 2Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 3Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 4Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 5Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 6Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 7Abbott's Kaletra(R) Tablet Dosed Once-Daily or Twice-Daily Demonstrated Similar Clinical Results Across Race and Gender Lines 8Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 2Tolerx Announces Achievement of Milestones upon anti-CD4 Antibody Program Advancement and Initiation of Phase 1 Clinical Trial 3
... precise and accurate Measurements! ,Patients are impressed ... examination when they see the doctor is ... - after only 5 minutes of proper ... proficient in the operation of this instrument ...
Great for small incisions and excision needs...
Multi-sided, Sharp all around...
...
Medicine Products: